Managing Director, Vulcan Capital
Consultant, MJTurner Consulting
CEO, Infectious Disease Research Institute
General Partner, Frazier Healthcare
President and CEO of Menlo Innovations
Managing Director, CommonAngels
Executive Director, NY Tech Meetup and Advisor, Flybridge Capital
CEO and Co-Founder of OnSwipe
|
Waiting for the biotech industry to advance new treatments for male pattern baldness (as well as female hair loss) might seem about as exciting as watching hair grow. But some people have a lot of skin in the game, if you know... Read more »
CardioKinetix has spent 10 years and $80 million in venture capital working on an implantable device for people with heart failure. Now it’s got some evidence that suggests it could be on track with a real product.
The Menlo Park, CA-based company is... Read more »
Drugs, devices, and nonprofits showed up in this week’s New England life sciences news.
—Promedior, a maker of treatments for tissue damage known as fibrosis, is moving its headquarters from Pennsylvania to Boston and has hired Suzanne Bruhn, a veteran of the Irish drug... Read more »
We’re anticipating a lot of news out of a big cancer conference that begins next week in Chicago. Here is your head start.
—Cancer researchers have talked for decades about finding the silver bullet that could kill cancer cells without harming the healthy cells... Read more »
A few years back, molecular geneticist Tom Maniatis was approached by a Harvard Business School student with a heart-wrenching story. The student, Avichai Kremer, then 29, had been diagnosed with amyotrophic lateral sclerosis (ALS), otherwise known as Lou Gehrig’s disease. Kremer had an... Read more »
From the moment Dendreon started in business 20 years ago, most scientists have said that if its immune-booster for prostate cancer was going to work, it would probably work best at an early stage of disease, before tumors had gotten too... Read more »
Aveo Oncology is entering a competitive world for the treatment of kidney cancer, and it made a bold bet that its drug would prevail in the first head-to-head comparison of its kind against an active drug. Now the company is preparing to... Read more »
Senior Partner, Bessemer Venture Partners
Co-Founder, Fate Therapeutics
Professor of Biomedical Engineering, Boston University
Chief Scientist, Mimecast
Visiting Scholar, MIT
San Francisco · 6/7/12
Xconomy offers a number of ways to subscribe for free!
Subscribe Now
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.
© 2007-2012, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.
Site produced by Andrew Koyfman with design from Rob Hunter.
